ArticleJournal of thrombosis and thrombolysis2026
Systemic immune-inflammation index predicts left atrial thrombus in non-valvular atrial fibrillation: A retrospective study of 847 patients.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Non-valvular atrial fibrillation (NVAF) serves as a primary cause of cardioembolic stroke, with left atrial thrombus (LAT) functioning as its major thrombotic substrate. The systemic immune-inflammation index (SII) has gained recognition as a dependable biomarker in cardiovascular disease. Nevertheless, its relationship with LAT in NVAF patients has not been thoroughly characterized in large-scale investigations. This retrospective study enrolled 847 NVAF patients who underwent transesophageal echocardiography (TEE). The primary outcome was TEE-detected left atrial thrombus (LAT). Patients were stratified into LAT-positive and LAT-negative groups. Univariable and multivariable logistic regression analyses identified independent predictors of LAT. Receiver operating characteristic (ROC) curve analysis evaluated the diagnostic performance of SII compared to the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and CHA₂DS₂-VASc score. Restricted cubic spline (RCS) analysis assessed the dose-response relationship between SII and LAT risk, and prespecified subgroup analyses examined whether this association remained consistent according to oral anticoagulant (OAC) use and other clinical strata. Of 847 patients, 142 (16.8%) were LAT-positive. Elevated SII was an independent predictor of LAT (OR = 1.13, 95% CI: 1.08-1.18 per 100-unit increase; P < 0.001) after adjusting for conventional risk factors. The optimal SII cutoff was 712.5 (AUC 0.786), showing slightly better discrimination than NLR, PLR, and CHA₂DS₂-VASc score. RCS analysis revealed a significant nonlinear dose-response relationship between SII and LAT risk, and the association remained consistent in both adequate-OAC and non-OAC subgroups. Elevated SII is independently associated with LAT in NVAF patients and offers useful discriminatory performance as an adjunct, rather than a standalone substitute, for established clinical assessment. As a readily accessible hematological parameter, SII may help identify patients with a low probability of LAT while supporting individualized decisions regarding TEE referral and anticoagulation management.
Indexed as
Identifiers
42177746What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.